Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system

Curtiss B. Cook, Linda J. Mann, Esther C. King, Katina M. New, Pamela S. Vaughn, Faye D. Dames, Virginia G. Dunbar, Jane M. Caudle, Circe Tsui, Christopher D. George, John P. McMichael

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The Intelligent Dosing System (IDSTM, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of the IDS for titrating insulin therapy. The IDS was placed on handheld platforms and provided to practitioners to use in adjusting total daily insulin dose. Fasting glucose, random glucose, and hemoglobin Alc were used as markers against which insulin could be adjusted. Values of markers expected at the next follow-up visit, as predicted by the model, were compared with levels actually observed. For 264 patients, 334 paired visits were analyzed. Average age was 54 years, diabetes' duration was 10 years, and body mass index was 33.2 kg/m 2; 57% were female, 88% were African American, and 92% had type 2 diabetes. The correlation between IDS suggested and actual prescribed total daily dose was high (r = 0.99), suggesting good acceptability of the IDS by practitioners. Significant decreases in fasting glucose, random glucose, and hemoglobin Alc levels were seen (all P < 0.0001). No significant difference between average expected and observed follow-up fasting glucose values was found (145 vs. 149 mg/dL, P = 0.42), and correlation was high (r = 0.79). Mean observed random glucose value at follow-up was comparable to the IDS predicted level (167 vs. 168 mg/dL, P = 0.97), and correlation was high (r = 0.73). Observed follow-up hemoglobin A1c was higher than the value expected (7.9% vs. 7.4%, P < 0.0055), but correlation was good (r = 0.70). These analyses suggest the IDS is a useful adjunct for decisions regarding insulin therapy even when using a variety of markers of glucose control, and can be used by practitioners to assist in attainment of glycemic goals.

Original languageEnglish (US)
Pages (from-to)326-335
Number of pages10
JournalDiabetes Technology and Therapeutics
Volume6
Issue number3
DOIs
StatePublished - Jun 2004

Fingerprint

Intelligent systems
Medical problems
Insulin
Glucose
Fasting
Hemoglobins
Therapeutics
African Americans
Type 2 Diabetes Mellitus
Body Mass Index
Theoretical Models
Software
Mathematical models

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Cook, C. B., Mann, L. J., King, E. C., New, K. M., Vaughn, P. S., Dames, F. D., ... McMichael, J. P. (2004). Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system. Diabetes Technology and Therapeutics, 6(3), 326-335. https://doi.org/10.1089/152091504774198016

Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system. / Cook, Curtiss B.; Mann, Linda J.; King, Esther C.; New, Katina M.; Vaughn, Pamela S.; Dames, Faye D.; Dunbar, Virginia G.; Caudle, Jane M.; Tsui, Circe; George, Christopher D.; McMichael, John P.

In: Diabetes Technology and Therapeutics, Vol. 6, No. 3, 06.2004, p. 326-335.

Research output: Contribution to journalArticle

Cook, CB, Mann, LJ, King, EC, New, KM, Vaughn, PS, Dames, FD, Dunbar, VG, Caudle, JM, Tsui, C, George, CD & McMichael, JP 2004, 'Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system', Diabetes Technology and Therapeutics, vol. 6, no. 3, pp. 326-335. https://doi.org/10.1089/152091504774198016
Cook, Curtiss B. ; Mann, Linda J. ; King, Esther C. ; New, Katina M. ; Vaughn, Pamela S. ; Dames, Faye D. ; Dunbar, Virginia G. ; Caudle, Jane M. ; Tsui, Circe ; George, Christopher D. ; McMichael, John P. / Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system. In: Diabetes Technology and Therapeutics. 2004 ; Vol. 6, No. 3. pp. 326-335.
@article{8af272da06cb4501a2a28b90a396a4f4,
title = "Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system",
abstract = "The Intelligent Dosing System (IDSTM, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of the IDS for titrating insulin therapy. The IDS was placed on handheld platforms and provided to practitioners to use in adjusting total daily insulin dose. Fasting glucose, random glucose, and hemoglobin Alc were used as markers against which insulin could be adjusted. Values of markers expected at the next follow-up visit, as predicted by the model, were compared with levels actually observed. For 264 patients, 334 paired visits were analyzed. Average age was 54 years, diabetes' duration was 10 years, and body mass index was 33.2 kg/m 2; 57{\%} were female, 88{\%} were African American, and 92{\%} had type 2 diabetes. The correlation between IDS suggested and actual prescribed total daily dose was high (r = 0.99), suggesting good acceptability of the IDS by practitioners. Significant decreases in fasting glucose, random glucose, and hemoglobin Alc levels were seen (all P < 0.0001). No significant difference between average expected and observed follow-up fasting glucose values was found (145 vs. 149 mg/dL, P = 0.42), and correlation was high (r = 0.79). Mean observed random glucose value at follow-up was comparable to the IDS predicted level (167 vs. 168 mg/dL, P = 0.97), and correlation was high (r = 0.73). Observed follow-up hemoglobin A1c was higher than the value expected (7.9{\%} vs. 7.4{\%}, P < 0.0055), but correlation was good (r = 0.70). These analyses suggest the IDS is a useful adjunct for decisions regarding insulin therapy even when using a variety of markers of glucose control, and can be used by practitioners to assist in attainment of glycemic goals.",
author = "Cook, {Curtiss B.} and Mann, {Linda J.} and King, {Esther C.} and New, {Katina M.} and Vaughn, {Pamela S.} and Dames, {Faye D.} and Dunbar, {Virginia G.} and Caudle, {Jane M.} and Circe Tsui and George, {Christopher D.} and McMichael, {John P.}",
year = "2004",
month = "6",
doi = "10.1089/152091504774198016",
language = "English (US)",
volume = "6",
pages = "326--335",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system

AU - Cook, Curtiss B.

AU - Mann, Linda J.

AU - King, Esther C.

AU - New, Katina M.

AU - Vaughn, Pamela S.

AU - Dames, Faye D.

AU - Dunbar, Virginia G.

AU - Caudle, Jane M.

AU - Tsui, Circe

AU - George, Christopher D.

AU - McMichael, John P.

PY - 2004/6

Y1 - 2004/6

N2 - The Intelligent Dosing System (IDSTM, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of the IDS for titrating insulin therapy. The IDS was placed on handheld platforms and provided to practitioners to use in adjusting total daily insulin dose. Fasting glucose, random glucose, and hemoglobin Alc were used as markers against which insulin could be adjusted. Values of markers expected at the next follow-up visit, as predicted by the model, were compared with levels actually observed. For 264 patients, 334 paired visits were analyzed. Average age was 54 years, diabetes' duration was 10 years, and body mass index was 33.2 kg/m 2; 57% were female, 88% were African American, and 92% had type 2 diabetes. The correlation between IDS suggested and actual prescribed total daily dose was high (r = 0.99), suggesting good acceptability of the IDS by practitioners. Significant decreases in fasting glucose, random glucose, and hemoglobin Alc levels were seen (all P < 0.0001). No significant difference between average expected and observed follow-up fasting glucose values was found (145 vs. 149 mg/dL, P = 0.42), and correlation was high (r = 0.79). Mean observed random glucose value at follow-up was comparable to the IDS predicted level (167 vs. 168 mg/dL, P = 0.97), and correlation was high (r = 0.73). Observed follow-up hemoglobin A1c was higher than the value expected (7.9% vs. 7.4%, P < 0.0055), but correlation was good (r = 0.70). These analyses suggest the IDS is a useful adjunct for decisions regarding insulin therapy even when using a variety of markers of glucose control, and can be used by practitioners to assist in attainment of glycemic goals.

AB - The Intelligent Dosing System (IDSTM, Dimensional Dosing Systems, Inc., Wexford, PA) is a software suite that incorporates patient-specific, dose-response data in a mathematical model and then calculates the new dose of agent needed to achieve the next desired therapeutic goal. We evaluated use of the IDS for titrating insulin therapy. The IDS was placed on handheld platforms and provided to practitioners to use in adjusting total daily insulin dose. Fasting glucose, random glucose, and hemoglobin Alc were used as markers against which insulin could be adjusted. Values of markers expected at the next follow-up visit, as predicted by the model, were compared with levels actually observed. For 264 patients, 334 paired visits were analyzed. Average age was 54 years, diabetes' duration was 10 years, and body mass index was 33.2 kg/m 2; 57% were female, 88% were African American, and 92% had type 2 diabetes. The correlation between IDS suggested and actual prescribed total daily dose was high (r = 0.99), suggesting good acceptability of the IDS by practitioners. Significant decreases in fasting glucose, random glucose, and hemoglobin Alc levels were seen (all P < 0.0001). No significant difference between average expected and observed follow-up fasting glucose values was found (145 vs. 149 mg/dL, P = 0.42), and correlation was high (r = 0.79). Mean observed random glucose value at follow-up was comparable to the IDS predicted level (167 vs. 168 mg/dL, P = 0.97), and correlation was high (r = 0.73). Observed follow-up hemoglobin A1c was higher than the value expected (7.9% vs. 7.4%, P < 0.0055), but correlation was good (r = 0.70). These analyses suggest the IDS is a useful adjunct for decisions regarding insulin therapy even when using a variety of markers of glucose control, and can be used by practitioners to assist in attainment of glycemic goals.

UR - http://www.scopus.com/inward/record.url?scp=3042695006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042695006&partnerID=8YFLogxK

U2 - 10.1089/152091504774198016

DO - 10.1089/152091504774198016

M3 - Article

VL - 6

SP - 326

EP - 335

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 3

ER -